ICD-10-CM 2027 diagnosis code
T44.4X5Adverse effect of predominantly alpha-adrenoreceptor agonists
T44.4X5 is a header code, so it can't be reported by itself. Choose one of the 3 more specific codes beneath it and add the required 7th character.Short description: Adverse effect of predominantly alpha-adrenocpt agonists
Code unchanged since ICD-10-CM took effect on October 1, 2015. Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data
About T44.4X5
T44.4X5 is the ICD-10-CM diagnosis code for adverse effect of predominantly alpha-adrenoreceptor agonists. It belongs to category T44 (poisoning by, adverse effect of and underdosing of drugs primarily affecting the autonomic nervous system), block T36-T50 (poisoning by, adverse effects of and underdosing of drugs, medicaments and biological substances) and chapter 19 (injury, poisoning and certain other consequences of external causes). It is a header code, so it can't be reported by itself; one of its 3 subcodes must be used instead.
Within T44.4X (poisoning by, adverse effect of and underdosing of predominantly alpha-adrenoreceptor agonists), T44.4X5 is specifically for adverse effect of predominantly alpha-adrenoreceptor agonists. Related codes cover poisoning by predominantly alpha-adrenoreceptor agonists, accidental (unintentional) (T44.4X1), poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm (T44.4X2), poisoning by predominantly alpha-adrenoreceptor agonists, assault (T44.4X3), poisoning by predominantly alpha-adrenoreceptor agonists, undetermined (T44.4X4) and underdosing of predominantly alpha-adrenoreceptor agonists (T44.4X6).
Codes in this range require a 7th character: A for initial encounter, D for subsequent encounter and S for sequela. Use placeholder "X" characters to fill any empty positions before the 7th character.
It has been part of ICD-10-CM since the code set took effect on October 1, 2015 and hasn't changed since.
7th character
The appropriate 7th character is to be added to each code from category T44
Notes that apply from higher levels
Instructions written at a parent level also apply to T44.4X5.
Table of Drugs & Neoplasms entries
- Agonist › predominantly › alpha-adrenoreceptor — Adverse effect
- Aplonidine — Adverse effect
- Apraclonidine (hydrochloride) — Adverse effect
- Cyclopentamine — Adverse effect
- Etilefrine — Adverse effect
- Gepefrine — Adverse effect
- Levarterenol — Adverse effect
- Metaraminol — Adverse effect
- Methoxamine — Adverse effect
- Noradrenaline — Adverse effect
- Norepinephrine — Adverse effect
- Norfenefrine — Adverse effect
- Oxedrine — Adverse effect
- Paredrine — Adverse effect
- Phenylephrine — Adverse effect
- Privine — Adverse effect
- Propyl › hexadrine — Adverse effect
Code history
- 2016
- 2017
- 2018
- 2019
- 2020
- 2021
- 2022
- 2023
- 2024
- 2025
- 2026
- 2027
- FY2016 (effective 10/1/2015): Added (first year of ICD-10-CM)
- No changes since FY2016.
Common questions about T44.4X5
Is T44.4X5 billable?
- No. T44.4X5 is a header code. Report one of its more specific subcodes instead.